SeaStar Medical Reports Second Quarter 2026 Financial Results and Provides Business Updates
Rhea-AI Summary
SeaStar Medical (Nasdaq: ICU) reported second quarter 2026 net revenue of $0.6 million, up 82% from $0.3 million a year earlier, driven by QUELIMMUNE product sales to an expanded base of 20 pediatric hospitals. Gross margin was approximately 91%.
Research and development expenses rose to $2.5 million and general and administrative expenses to $1.8 million, leading to a net loss of $3.7 million, or $0.91 per share, versus a $2.0 million loss in 2025. Cash was $7.0 million at June 30, 2026, down from $12.0 million at year-end 2025.
The NEUTRALIZE-AKI pivotal trial in adult AKI has enrolled 223 of 339 patients, with enrollment completion anticipated around late 2026 or early 2027. SeaStar Medical also obtained dedicated ICD-10-PCS codes for its SCD therapy effective October 1, 2026, supporting hospital billing for inpatient AKI treatment.
Positive
- Net revenue $0.615M in Q2 2026, up 82% year over year
- QUELIMMUNE customers 20 pediatric hospitals after adding three top-rated centers
- Gross margin ~91% in Q2 2026 on $0.6M net revenue
- NEUTRALIZE-AKI trial enrollment 223/339 adult AKI patients as of the update
- ICD-10-PCS codes granted for SCD therapy, effective October 1, 2026
- Other income (net) +$0.1M versus a $0.2M net expense in Q2 2025
Negative
- Net loss $3.7M in Q2 2026 versus $2.0M year over year
- R&D expenses $2.5M in Q2 2026 versus $1.0M in Q2 2025
- G&A expenses $1.8M in Q2 2026 versus $1.0M in Q2 2025
- Cash balance $7.0M at June 30, 2026, down from $12.0M at December 31, 2025
- Accumulated deficit $159.0M as of June 30, 2026
- Shares outstanding 4.26M at June 30, 2026, up from 3.84M at December 31, 2025
News Explained
The larger share base can reduce existing holders’ percentage ownership: 4,259,842 shares were outstanding at June 30 versus 3,844,613 at year-end.
SeaStar reported its second-quarter results on
That is the disclosed dilution mechanism: issuing additional shares increases the total share count and reduces an existing holder’s percentage ownership.
For liquidity context, cash at
Sources and calculations
- SeaStar Medical Reports Second Quarter 2026 Financial Results and Provides Business Updates (2026-08-12)
- Dilution
- SeaStar Medical first-quarter 2026 fundamentals (2026Q1)
- Cash and equivalents vs quarterly operating cash outflow, in days of cash use $9,348,000 / ($2,761,000 / 90) = [object Object]
Market reaction after 2Q26 earnings report: ICU -4.54%
Following this news, ICU has declined 4.54%, reflecting a moderate negative market reaction. Our momentum scanner has triggered 14 alerts so far, indicating notable trading interest and price volatility. The stock is currently trading at $3.21. Trading volume is elevated at 2.4x the average, suggesting increased selling activity.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 13 | Q1 earnings report | Positive | -8.7% | Revenue growth, trial enrollment, and registry progress accompanied a negative reaction. |
| Mar 25 | Q4 earnings report | Positive | +22.4% | Revenue growth, trial enrollment, and cash improvement accompanied a positive reaction. |
| Nov 13 | Q3 earnings report | Positive | -17.4% | Positive trial signals, registry data, and financing activity accompanied a negative reaction. |
| Aug 13 | Q2 earnings report | Positive | +21.0% | Revenue, trial enrollment, customer additions, and financing activity accompanied a positive reaction. |
| May 14 | Q1 earnings report | Positive | +0.8% | Revenue growth, trial enrollment, and improved net loss accompanied a positive reaction. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings-specific history showed three aligned positive reactions and two divergences, indicating generally favorable but inconsistent market follow-through.
Key Terms
acute kidney injury medical
premarket approval (pma) regulatory
icd-10-pcs regulatory
continuous renal replacement therapy medical
humanitarian device exemption regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Added 3 top-rated children’s hospitals to QUELIMMUNE® pediatric acute kidney injury (AKI) customer base, increasing net revenue
Advanced enrollment in the NEUTRALIZE-AKI pivotal clinical trial in adult patients with AKI
Obtained ICD-10-PCS codes to enable standardized inpatient hospital billing for its selective cytopheretic device (SCD) therapy, including QUELIMMUNE
Webcast today at 4:30 pm Eastern Time
DENVER, Aug. 12, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life, announced today financial results for the three months ended June 30, 2026, and provided business updates on key initiatives.
“The enthusiasm for the use of our QUELIMMUNE therapy is resonating broadly throughout the pediatric critical care community,” said Eric Schlorff, CEO of SeaStar Medical. “We believe our continued QUELIMMUNE revenue growth bodes well for our future potential opportunity in the adult AKI market that is 50 times larger than the current pediatric market in the U.S.”
Mr. Schlorff continued, “We are keenly focused on achieving our enrollment target of 339 adult AKI patients in the NEUTRALIZE-AKI trial, and we are working with the FDA on our modular Premarket Approval (PMA) application for our SCD therapy as an organ-sparing and life-saving treatment for the adult patient population. With strong gross margins for QUELIMMUNE and universal ICD-10-PCS codes already established for our SCD therapies, we believe this first-in-class therapy for the treatment of adult patients with AKI has clear potential to both save lives and create significant shareholder value, should we obtain FDA approval.”
Key Business Highlights
SeaStar Medical’s achievements since the beginning of the second quarter of 2026 include the following:
- Expanded the use of QUELIMMUNE (SCD-PED) therapy for ultra-rare pediatric AKI, adding 3 new customers from top-rated children’s hospitals, bringing the total customer base to 20 and building increased depth in customer orders. This led to second quarter 2026 net revenue of
$0.6 million for QUELIMMUNE product sales, an increase of82% versus the second quarter of 2025. - Advanced enrollment in the NEUTRALIZE-AKI pivotal clinical trial evaluating the SCD therapy as a potential treatment of adult patients with AKI in the ICU receiving continuous renal replacement therapy. The trial has enrolled 223 of 339 patients to date. Completion of enrollment is anticipated around year end or into the first quarter of 2027, which would enable a PMA application to the FDA near the end of 2027, pending a positive outcome of the trial.
- Received from the Centers for Medicare & Medicaid Services (CMS) dedicated International Classification of Diseases, 10th Revision, Procedure Coding System (ICD-10-PCS) codes. These codes enable administrative, billing, and statistical reporting for the use of SeaStar Medical’s SCD therapy in patients with AKI requiring renal replacement therapy in the inpatient hospital setting. The new ICD-10-PCS codes are expected to take effect on October 1, 2026.
- Sponsored and participated in the KidneyBee Summit 2026. The Summit, which occurs annually, is a highly specialized, interdisciplinary conference that brings together nurses, advanced practice providers, and physicians from across the country. Its core importance stems from tackling the exact systemic failures that leave pediatric kidney failure under-recognized.
- Assembled leading experts in the treatment of pediatric AKI to speak at the SeaStar Medical educational webinar, “Rethinking Pediatric Sepsis-Associated AKI,” that brought together practicing pediatric nephrologists, critical care physicians, advanced practice providers, nurses, and critical care teams to learn more about pediatric sepsis-associated AKI and the use of the QUELIMMUNE therapy.
Financial Results for the Second Quarter 2026
Net revenue for the three months ended June 30, 2026, was approximately
Cost of goods sold for the three months ended June 30, 2026, and 2025, was
Research and development expenses for the three months ended June 30, 2026, and 2025, were
General and administrative expenses for the three months ended June 30, 2026, and 2025, were approximately
Other income (net) was
Net loss for the three months ended June 30, 2026, was approximately
Cash at June 30, 2026, was
| SeaStar Medical Second Quarter Financial Results Conference Call | |
| Date/Time: | Wednesday, August 12, 2026, at 4:30 p.m. ET / 2:30 p.m. MT |
| Webcast: | The live webcast and replay can be found here. |
| Register for the call: | Preregistration is required to attend the live call and can be accessed here. A pin code and dial in number will be provided with registration. |
| A replay of the call will be available after 7:30 p.m. ET and can be accessed here. | |
About QUELIMMUNE
The QUELIMMUNE® (SCD-PED) therapy is being commercialized for children with AKI and sepsis or septic condition weighing 10 kilograms or more who are on antibiotics and being treated in the ICU with RRT. It was approved in February 2024 under a Humanitarian Device Exemption application.
Data from two clinical trials of the QUELIMMUNE therapy, published in Kidney Medicine, showed a
The patented technology behind QUELIMMUNE is known as the Selective Cytopheretic Device (SCD) therapy and has broad applications for treating the destructive hyperinflammation that shuts down organ function and causes loss of life.
About the SeaStar Medical Selective Cytopheretic Device (SCD) Therapy
The SCD therapy is designed as a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation and creates a cascade of events that wreak havoc in the patient’s body. The SCD therapy is designed for broad applications in multiple acute and chronic kidney and cardiovascular diseases, representing patients who today have no FDA-approved options for treating their disease. Unlike pathogen removal and other blood-purification tools, the SCD therapy is integrated with an existing continuous RRT hemofiltration system to selectively target and transition proinflammatory monocytes to a reparative state and promote activated neutrophils to be less inflammatory. This unique immunomodulation approach may promote long-term organ recovery, eliminate the need for future continuous RRT, including dialysis, and prevent loss of life.
About NEUTRALIZE-AKI Pivotal Trial
The NEUTRALIZE-AKI (NEUTRophil and monocyte deActivation via SeLective Cytopheretic Device – a randomIZEd clinical trial in Acute Kidney Injury) pivotal trial is evaluating the safety and efficacy of the SCD therapy in 339 adults with AKI in the ICU receiving continuous RRT. The trial’s primary endpoint is a composite of 90-day mortality or dialysis dependency of patients treated with the SCD therapy in addition to continuous RRT as the standard of care, compared with the control group receiving only continuous RRT standard of care. Secondary endpoints include mortality at 28 days, ICU-free days in the first 28 days, major adverse kidney events at Day 90 and dialysis dependency at one year. The study will also include subgroup analyses to explore the effectiveness of the SCD therapy in AKI patients with sepsis and acute respiratory distress syndrome.
About Acute Kidney Injury (AKI) and Hyperinflammation
AKI is characterized by a sudden and temporary loss of kidney function and can be caused by a variety of conditions such as severe infections or other septic conditions, severe trauma, surgery, and organ failures. AKI can cause destructive hyperinflammation, which is the overproduction or overactivity of inflammatory effector cells and other molecules that can be toxic. Damage resulting from this destructive hyperinflammation in AKI can progress to other organs, such as the heart or liver, and potentially to multi-organ dysfunction or even failure that could result in worse outcomes, including increased risk of death. Even after resolution, these patients may face complications including chronic kidney disease or end-stage renal disease (ESRD) requiring dialysis. Extreme hyperinflammation may also contribute to added healthcare costs, such as prolonged ICU stays and increased reliance on dialysis and mechanical ventilation.
About SeaStar Medical
SeaStar Medical is a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life. SeaStar Medical’s first commercial product, QUELIMMUNE (SCD-PED), was approved in 2024 by the U.S. Food and Drug Administration (FDA). It is the only FDA approved product for the ultra-rare condition of life-threatening Acute Kidney Injury (AKI) due to sepsis or a septic condition requiring renal replacement therapy (RRT) in critically ill pediatric patients. SeaStar Medical’s Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for six therapeutic indications by the FDA, enabling the potential for a speedier pathway to approval and preferable reimbursement dynamics at commercial launch. The company is currently conducting the NEUTRALIZE-AKI pivotal clinical trial of its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy, a life-threatening condition with no effective treatment options that impacts over 200,000 adults in the U.S. annually.
For more information visit www.seastarmedical.com or visit us on LinkedIn or X.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1955. These forward-looking statements include, without limitation, SeaStar Medical’s expectations with respect our future potential opportunity in the adult AKI market; the size of the adult AKI market compared to the pediatric market; commercial acceptance of QUELIMMUNE; the ability of SCD to treat patients with AKI and other diseases; ; the anticipated timing of regulatory submissions; the ability to meet our enrollment targets; the ability to create shareholder value; the expected regulatory approval process and timeline for commercialization; and the ability of SeaStar Medical to meet the expected timeline. Words such as “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside SeaStar Medical’s control and are difficult to predict. Factors that may cause actual future events to differ materially from the expected results include, but are not limited to: (i) the risk that SeaStar Medical may not be able to obtain regulatory approval of its SCD product candidates; (ii) the risk that SeaStar Medical may not be able to raise sufficient capital to fund its operations, including current or future clinical trials; (iii) the risk that SeaStar Medical and its current and future collaborators are unable to successfully develop and commercialize its products or services, or experience significant delays in doing so, including failure to achieve approval of its products by applicable federal and state regulators, (iv) the risk that SeaStar Medical may never achieve or sustain profitability; (v) the risk that SeaStar Medical may not be able to secure additional financing on acceptable terms; (vi) the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations, (vii) the risk of product liability or regulatory lawsuits or proceedings relating to SeaStar Medical’s products and services, (viii) the risk that SeaStar Medical is unable to secure or protect its intellectual property, and (ix) other risks and uncertainties indicated from time to time in SeaStar Medical’s Annual Report on Form 10-K, including those under the “Risk Factors” section therein and in SeaStar Medical’s other filings with the SEC. The foregoing list of factors is not exhaustive. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and SeaStar Medical assumes no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.
Contact:
IR@SEASTARMED.COM
| SeaStar Medical Holding Corporation Condensed Consolidated Balance Sheets (in thousands, except for share and per-share amounts) | ||||||||
| June 30, 2026 | December 31, 2025 | |||||||
| (unaudited) | ||||||||
| ASSETS | ||||||||
| Current assets | ||||||||
| Cash | $ | 6,959 | $ | 11,980 | ||||
| Accounts receivable, net of allowance for credit losses of | 208 | 237 | ||||||
| Inventory | 77 | 66 | ||||||
| Prepaid expenses | 984 | 1,297 | ||||||
| Total current assets | 8,228 | 13,580 | ||||||
| Other assets | 421 | 578 | ||||||
| Total assets | $ | 8,649 | $ | 14,158 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY/(DEFICIT) | ||||||||
| Current liabilities | ||||||||
| Accounts payable | $ | 750 | 948 | |||||
| Accrued expenses | 3,468 | 2,268 | ||||||
| Notes payable, net of deferred financing costs | 134 | 525 | ||||||
| Liability classified warrants | 1 | 1 | ||||||
| Total current liabilities | 4,353 | 3,742 | ||||||
| Total liabilities | 4,353 | 3,742 | ||||||
| Commitments and contingencies (Note 10) | ||||||||
| Stockholders’ equity | ||||||||
| Preferred stock - | — | — | ||||||
| Common stock - | 4 | 4 | ||||||
| Additional paid-in capital | 163,257 | 162,126 | ||||||
| Accumulated deficit | (158,965 | ) | (151,714 | ) | ||||
| Total stockholders’ equity | 4,296 | 10,416 | ||||||
| Total liabilities and stockholders’ equity | $ | 8,649 | $ | 14,158 | ||||
| SeaStar Medical Holding Corporation Condensed Consolidated Statements of Operations (unaudited) (in thousands, except for share and per-share amounts) | ||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Net revenue | $ | 615 | $ | 338 | $ | 1,110 | $ | 631 | ||||||||
| Cost of goods sold | 54 | 27 | 100 | 27 | ||||||||||||
| Gross profit | 561 | 311 | 1,010 | 604 | ||||||||||||
| Operating expenses | ||||||||||||||||
| Research and development | 2,520 | 1,037 | 4,864 | 3,468 | ||||||||||||
| General and administrative | 1,832 | 1,030 | 3,540 | 2,716 | ||||||||||||
| Total operating expenses | 4,352 | 2,067 | 8,404 | 6,184 | ||||||||||||
| Loss from operations | (3,791 | ) | (1,756 | ) | (7,394 | ) | (5,580 | ) | ||||||||
| Other income (expense) | ||||||||||||||||
| Interest income | 69 | 45 | 160 | 93 | ||||||||||||
| Interest expense | (8 | ) | (9 | ) | (14 | ) | (18 | ) | ||||||||
| Other financing costs | — | (298 | ) | — | (298 | ) | ||||||||||
| Change in fair value of warrants liability | — | 16 | — | 32 | ||||||||||||
| Total other income (expense), net | 61 | (246 | ) | 146 | (191 | ) | ||||||||||
| Loss before provision for income taxes | (3,730 | ) | (2,002 | ) | (7,248 | ) | (5,771 | ) | ||||||||
| Provision for income taxes | — | — | 3 | 3 | ||||||||||||
| Net loss | $ | (3,730 | ) | $ | (2,002 | ) | $ | (7,251 | ) | $ | (5,774 | ) | ||||
| Net loss per share of common stock, basic and diluted | $ | (0.91 | ) | $ | (1.77 | ) | $ | (1.81 | ) | $ | (5.78 | ) | ||||
| Weighted-average shares outstanding, basic and diluted | 4,084,283 | 1,132,952 | 4,001,770 | 998,122 | ||||||||||||
| SeaStar Medical Holding Corporation Condensed Consolidated Statements of Cash Flows (unaudited) (in thousands) | ||||||||
| Six Months Ended June 30, | ||||||||
| 2026 | 2025 | |||||||
| Cash flows from operating activities | ||||||||
| Net loss | $ | (7,251 | ) | $ | (5,774 | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities | ||||||||
| Amortization of deferred financing costs | 14 | 18 | ||||||
| Change in fair value of liability classified warrants | — | (32 | ) | |||||
| Shares issued for the standby equity purchase agreement commitment fee | — | 298 | ||||||
| Stock-based compensation | (8 | ) | 264 | |||||
| Change in operating assets and liabilities | ||||||||
| Accounts receivables | 29 | (105 | ) | |||||
| Inventory | (11 | ) | (77 | ) | ||||
| Prepaid expenses | 313 | 784 | ||||||
| Other assets | 157 | 156 | ||||||
| Accounts payable | (198 | ) | 112 | |||||
| Accrued expenses | 1,200 | (1,305 | ) | |||||
| Net cash used in operating activities | (5,755 | ) | (5,661 | ) | ||||
| Cash flows from financing activities | ||||||||
| Proceeds from issuance of shares, net of offering costs | 1,139 | 5,154 | ||||||
| Proceeds from exercise warrants | — | 2 | ||||||
| Proceeds of pre-funded warrants | — | 5,580 | ||||||
| Payment of notes payable | (405 | ) | (592 | ) | ||||
| Net cash provided by financing activities | 734 | 10,144 | ||||||
| Net increase (decrease) in cash | (5,021 | ) | 4,483 | |||||
| Cash, beginning of period | 11,980 | 1,819 | ||||||
| Cash, end of period | $ | 6,959 | $ | 6,302 | ||||
QUELIMMUNE is a registered trademark of SeaStar Medical Holding Corporation.
